Stocksigma LogoStocksigma Logo

Gland Pharma Receives Zero Form 483 Observations from USFDA

Gland Pharma announced the conclusion of a USFDA inspection at its VSEZ Sterile Oncology Formulations and API Facility in Visakhapatnam

Gland Pharma Receives Zero Form 483 Observations from USFDA

Gland Pharma Ltd · Others (Uncategorized) · 01 Sept 2026, 9:19 pm

Gland Pharma Receives Zero Form 483 Observations from USFDA Gland Pharma announced the conclusion of a USFDA inspection at its VSEZ Sterile Oncology Formulations and API Facility in Visakhapatnam. The routine Good Manufacturing Practice (GMP) inspection, conducted from 24th Aug’26 to 1st Sep’26, concluded with ZERO (0) Form 483 observations. This favorable outcome is a significant positive, indicating compliance with US regulatory standards and mitigating risks of supply disruptions from this key facility. The company stated there is no financial or operational impact.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements